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Radiotherapy to the primary tumour has been 
much discussed as a possible intervention in 
patients with newly diagnosed metastatic pros-
tate cancer. Results of the STAMPEDE trial 
indicate that overall no survival advantage can 
be achieved by the addition of radiotherapy. 
However, patients with low volume, oligo-
metastatic disease were shown to benefit in a 
predefined subgroup analysis. In the current 
podcast Dr. Parker provides insight on the 
practice changing impact of the STAMPEDE 
trial and gives an outlook what is next on the 
horizon in metastatic prostate cancer therapy.
Competing interests None declared.
Patient consent Not required.
Provenance and peer review Commissioned; internally peer 
reviewed.
Open access This is an open access article distributed 
in accordance with the Creative Commons Attribution Non 
Commercial (CC BY-NC 4.0) license, which permits others to 
distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the 
original work is properly cited, any changes made are indicated, 
and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4.0
Click here to listen to the Podcast
 o
n
 20 June 2019 by guest. Protected by copyright.
http://esm
oopen.bmj.com/
ESM
O
 O
pen: first published as 10.1136/esm
oopen-2018-000451 on 21 O
ctober 2018. Downloaded from
 
